Functional Selectivity and Classical Concepts of Quantitative Pharmacology

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2007-01-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.106.104463PMID 16803859
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopamine Receptors

  2008cited by this paper
• Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways

  2007cited by this paper
• Serotonin 5‐HT2A receptor activation induces 2‐arachidonoylglycerol release through a phospholipase c‐dependent mechanism

  2006influential reference
• Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

  2006cited by this paper
• The structure and dynamics of GPCR oligomers: a new focus in models of cell-signaling mechanisms and drug design.

  2005cited by this paper
• Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation.

  2005influential reference
• Therapeutic targeting of α4‐integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit?

  2005cited by this paper
• New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism

  2005cited by this paper
• Differential phospholipase C activation by phenylalkylamine serotonin 5‐HT2A receptor agonists

  2005cited by this paper
• Nephrogenic syndrome of inappropriate antidiuresis.

  2005cited by this paper
• Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors

  2005influential reference
• Natalizumab and PML

  2005cited by this paper
• Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells.

  2005cited by this paper
• Differential Activation of Adenylate Cyclase and Receptor Internalization by Novel Dopamine D1 Receptor Agonists

  2005cited by this paper
• Probing the β2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists*

  2005influential reference
• A pathophysiological paradigm for the therapy of psychiatric disease

  2005cited by this paper
• Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery

  2005influential reference
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

  2005cited by this paper
• Constitutive Activity of the Serotonin2C Receptor Inhibits In Vivo Dopamine Release in the Rat Striatum and Nucleus Accumbens

  2004cited by this paper
• Principles for modulation of the nuclear receptor superfamily

  2004cited by this paper
• Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1α

  2004cited by this paper
• A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin interface

  2004cited by this paper
• Closed state of both binding domains of homodimeric mGlu receptors is required for full activity

  2004cited by this paper
• Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

  2004cited by this paper
• Quantitative Information Management for the Biochemical Computation of Cellular Networks

  2004cited by this paper
• Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies.

  2004cited by this paper
• Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states.

  2004influential reference
• Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states.

  2004cited by this paper
• The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells

  2004cited by this paper
• Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone

  2004cited by this paper
• Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes*

  2003cited by this paper
• Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands.

  2003cited by this paper
• Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy.

  2003influential reference
• Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein.

  2003cited by this paper
• Activation-independent Parathyroid Hormone Receptor Internalization Is Regulated by NHERF1 (EBP50)*

  2003cited by this paper
• Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

  2003influential reference
• Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex

  2003cited by this paper
• A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases

  2003influential reference
• Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves

  2003influential reference
• 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens.

  2002cited by this paper
• G Protein-Coupled Receptor Allosterism and Complexing

  2002cited by this paper
• Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.

  2002cited by this paper
• μ-Opioid Receptors: Ligand-Dependent Activation of Potassium Conductance, Desensitization, and Internalization

  2002cited by this paper
• Three-dimensional representations of G protein-coupled receptor structures and mechanisms.

  2002cited by this paper
• Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.

  2002cited by this paper
• Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence.

  2002cited by this paper
• Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+

  2002cited by this paper
• Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

  2002influential reference
• Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.

  2002influential reference
• Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization.

  2002influential reference
• Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor.

  2002cited by this paper
• Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis.

  2002cited by this paper
• Use of fluorescence spectroscopy to study conformational changes in the beta 2-adrenoceptor.

  2002cited by this paper
• Conserved Helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor

  2002cited by this paper
• Constitutive Activation and Endocytosis of the Complement Factor 5a Receptor: Evidence for Multiple Activated Conformations of a G Protein‐Coupled Receptor

  2002cited by this paper
• Chapter 1. Promise and progress of central G-protein coupled receptor modulators for obesity treatments

  2002cited by this paper
• Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor*

  2001cited by this paper
• Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus.

  2001cited by this paper
• The Dynamin-dependent, Arrestin-independent Internalization of 5-Hydroxytryptamine 2A (5-HT2A) Serotonin Receptors Reveals Differential Sorting of Arrestins and 5-HT2A Receptors during Endocytosis* 210

  2001cited by this paper
• Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

  2001cited by this paper
• Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists.

  2001cited by this paper
• Differences in conformational properties of the second intracellular loop (IL2) in 5HT(2C) receptors modified by RNA editing can account for G protein coupling efficiency.

  2001cited by this paper
• RNA‐editing of the 5‐HT2C receptor alters agonist‐receptor‐effector coupling specificity

  2001cited by this paper
• Three-dimensional structure of an invertebrate rhodopsin and basis for ordered alignment in the photoreceptor membrane.

  2001cited by this paper
• Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

  2001cited by this paper
• Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists.

  2000cited by this paper
• Biomedical Applications of Computer Modeling

  2000cited by this paper
• From the Static to the Dynamic: Three Models of Signal Transduction in G Protein-Coupled Receptors

  2000cited by this paper
• Regulation of 5-HT(2A) receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin.

  2000cited by this paper
• Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor

  2000cited by this paper
• Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo.

  1999influential reference
• The assessment of antagonist potency under conditions of transient response kinetics.

  1999cited by this paper
• Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

  1999cited by this paper
• Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction.

  1999cited by this paper
• Morphine-activated opioid receptors elude desensitization by beta-arrestin.

  1998cited by this paper
• mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain.

  1998cited by this paper
• Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.

  1998cited by this paper
• The elusive nature of intrinsic efficacy.

  1998cited by this paper
• Morphine-activated opioid receptors elude desensitization by β-arrestin

  1998cited by this paper
• Dopamine receptor subtypes : from basic science to clinical application

  1998cited by this paper
• Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

  1998cited by this paper
• Pleiotropic Behavior of 5‐HT2A and 5‐HT2C Receptor Agonists

  1998cited by this paper
• beta-Adrenergic-receptor kinase

  1997cited by this paper
• Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist.

  1997cited by this paper
• Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor.

  1997cited by this paper
• Mianserin‐Induced Down‐Regulation of Human 5‐Hydroxytryptamine2A and 5‐Hydroxytryptamine2C Receptors Stably Expressed in the Human Neuroblastoma Cell Line SH‐SY5Y

  1997cited by this paper
• Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor

  1997cited by this paper
• μ Opioid Receptor Phosphorylation, Desensitization, and Ligand Efficacy*

  1997cited by this paper
• Molecular Drug Design and Dopamine Receptors

  1997influential reference
• Mu opioid receptor phosphorylation, desensitization, and ligand efficacy.

  1997cited by this paper
• Morphine Activates Opioid Receptors without Causing Their Rapid Internalization*

  1996cited by this paper
• Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro.

  1996cited by this paper
• Agonist-selective endocytosis of mu opioid receptor by neurons in vivo.

  1996cited by this paper
• Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.

  1996cited by this paper
• 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

  1995cited by this paper
• Inverse agonism: theory and practice.

  1995cited by this paper
• Pharmacological proteus?

  1995cited by this paper
• Kenakin replies: Efficacy as the molecular property of a ligand

  1995cited by this paper
• Pharmacologic analysis of drug-receptor interaction

  1994cited by this paper
• International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

  1994cited by this paper

• Targeting serotonin 5-HT2A receptors in the treatment of aggression: From antipsychotics to psychedelics

  2026cites this paper
• Dynamic-GLEP: a dynamics-informed deep learning framework for ligand efficacy prediction in representative Class A GPCRs

  2026cites this paper
• Selective activation of cannabinoid receptors by cannabis terpenes.

  2025cites this paper
• Pharmacologie des opioïdes

  2025cites this paper
• Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.

  2025cites this paper
• Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs.

  2025cites this paper
• Biased Signaling and Its Role in the Genesis of Short- and Long-Acting β2‑Adrenoceptor Agonists

  2025cites this paper
• 5-HT2A receptors: Pharmacology and functional selectivity

  2025cites this paper
• Clinical pharmacology.

  2025cites this paper
• Repurposing drugs for the human dopamine transporter through WHALES descriptors-based virtual screening and bioactivity evaluation

  2025cites this paper
• Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence

  2025cites this paper
• Farmacologia degli oppioidi

  2025cites this paper
• Intracellular GPCR modulators enable precision pharmacology

  2025cites this paper
• Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function

  2025cites this paper
• Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases.

  2025cites this paper
• Unraveling allosteric signaling of G protein-coupled receptors (GPCRs) by single-molecule fluorescence

  2025cites this paper
• Beta‐Arrestin2‐Biased Activation by Pilocarpine Suppresses Microglial Inflammatory Response

  2025cites this paper
• Application of the C-BED tool in the analysis of the effect of norfluoxetine as an EDC on the marine mussel Mytilus trossulus

  2025cites this paper
• Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2

  2025influential citation
• Insights into Ligand-Specific Activation Dynamics of Dopamine D2 Receptor Explored by MD Simulations

  2025cites this paper
• Biased Signaling in Psychedelic Action.

  2025cites this paper
• Orally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of β-Arrestin in Treatment-Related Dyskinesia in Parkinson's Disease.

  2025cites this paper
• Biased signaling in drug discovery and precision medicine.

  2025cites this paper
• Estimation of Dopamine D1 Receptor Agonist Binding Kinetics Using Time-Resolved Functional Assays: Relation to Agonist-Induced Receptor Internalization by Investigational Antiparkinsonian Therapeutics

  2025cites this paper
• Canonical or non‐canonical, all aspects of G protein‐coupled receptor kinase 2 in heart failure

  2025cites this paper
• Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review.

  2025cites this paper
• Single-Molecule Insights into GPCR Conformational Landscapes

  2025cites this paper
• A Review on the Potential of Biased Agonism in the GPCR Signalosome for Therapeutic Efficacy

  2025cites this paper
• Functionally Selective Dopamine D1 Receptor Endocytosis and Signaling by Catechol and Noncatechol Agonists.

  2025cites this paper
• Biased Signaling in G Protein-Coupled Receptors: Understanding the Biological Relevance and Tools for Probing Functionally Selective Ligands.

  2025cites this paper
• Conformational Heterogeneity Underlying Divergent Signaling in Class A G Protein-Coupled Receptors.

  2025cites this paper
• Go/z-biased coupling profile of the dopamine D3 receptor

  2025cites this paper
• Biased GPCR Signaling: Possible Mechanisms and Therapeutic Applications.

  2025cites this paper
• Canonical Cannabinoid Receptors.

  2025cites this paper
• History of psychedelic drug science and molecular pharmacology.

  2025cites this paper
• Exploring Bias in GPCR Signaling and its Implication in Drug Development: A One-Sided Affair.

  2024cites this paper
• Nalbuphine Nasal Spray: Analgesic Efficacy and Safety

  2024cites this paper
• Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review

  2024cites this paper
• A massively parallel reporter assay library to screen short synthetic promoters in mammalian cells

  2024cites this paper
• GRK specificity and Gβγ dependency determines the potential of a GPCR for arrestin-biased agonism

  2024cites this paper
• The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.

  2024cites this paper
• Association of histone modification with the development of schizophrenia.

  2024cites this paper
• Opioid-Induced Inter-regional Dysconnectivity Correlates with Analgesia in Awake Mouse Brains

  2024cites this paper
• Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor

  2024cites this paper
• Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.

  2024cites this paper
• Mechanisms of biased agonism by Gαi/o-biased stapled peptide agonists of the relaxin-3 receptor

  2024cites this paper
• Involvement of serotonergic receptors in depressive processes and their modulation by β-arrestins: A review

  2024cites this paper
• Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists.

  2024cites this paper
• Dopamine D1 receptor agonists rescue age-related decline in temporal order memory.

  2024cites this paper
• Fundamental Mechanisms in Membrane Receptology: Old Paradigms, New Concepts and Perspectives

  2024cites this paper
• Molecular glues as potential GPCR therapeutics.

  2024cites this paper
• Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons

  2024cites this paper
• Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology.

  2024cites this paper
• Ligand bias at the muscarinic acetylcholine receptor family: opportunities and challenges.

  2024cites this paper
• Characterization of Gαs and Gαolf activation by catechol and non-catechol dopamine D1 receptor agonists

  2024cites this paper
• PAR2 biased signaling on the move.

  2024cites this paper
• Impacts of exposure to and subsequent discontinuation of clozapine on tripartite synaptic transmission

  2024cites this paper
• GRK specificity and Gβγ dependency determines a GPCR’s potential in biased agonism

  2023cites this paper
• The "E-RAISE Model" exploration of science challenges and cultural values improves learning outcomes

  2023cites this paper
• G protein-biased LPAR1 agonism of prototypic antidepressants: Implication in the identification of novel therapeutic target for depression

  2023cites this paper
• Enhanced Bystander BRET (ebBRET) Biosensors as Biophysical Tools to Map the Signaling Profile of Neuropsychiatric Drugs Targeting GPCRs.

  2023cites this paper
• Chemistry, Crystal Structure, and In Vitro Receptor Binding of Δ10-THC Isomers

  2023cites this paper
• Molecular Dynamics and Machine Learning Study of Adrenaline Dynamics in the Binding Pocket of GPCR

  2023cites this paper
• Wnt signaling is involved in crotalphine-induced analgesia in a rat model of neuropathic pain.

  2023cites this paper
• Comparative study of the molecular mechanisms underlying the G protein and β‐arrestin‐dependent pathways that lead to ERKs activation upon stimulation by dopamine D2 receptor

  2023cites this paper
• Biased Dopamine D2 Receptors Exhibit Distinct Intracellular Trafficking Properties and ERK Activation in Different Subcellular Domains

  2023cites this paper
• Quantitative receptor model for responses that are left- or right-shifted versus occupancy (are more or less concentration sensitive): the SABRE approach

  2023cites this paper
• Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases

  2023cites this paper
• Characterization of behavioral changes in T-maze alternation from dopamine D1 agonists with different receptor coupling mechanisms

  2023cites this paper
• Mas receptor: a potential strategy in the management of ischemic cardiovascular diseases

  2023cites this paper
• Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

  2023cites this paper
• G protein coupled receptors as targets for transformative neuropsychiatric therapeutics.

  2023cites this paper
• Gα Protein Signaling Bias at Serotonin 1A Receptor

  2023cites this paper
• Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism

  2023cites this paper
• The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice

  2023cites this paper
• G protein-coupled receptors (GPCRs) as Potential Therapeutics for Psychiatric Disorders.

  2023cites this paper
• Pharmacological blockade of the Interleukin-1 receptor suppressed E. coli lipopolysaccharide-induced neuroinflammation in preterm fetal sheep.

  2023cites this paper
• Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness

  2023cites this paper
• The role of G protein-coupled receptor in neutrophil dysfunction during sepsis-induced acute respiratory distress syndrome

  2023cites this paper
• Biological studies of clavine alkaloids targeting CNS receptors

  2023cites this paper
• An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture

  2023cites this paper
• The crosstalk between 5-HT2AR and mGluR2 in schizophrenia.

  2023cites this paper
• Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

  2023cites this paper
• Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine D2 and D3 Receptors and Their Impact on Behavioral Sensitization

  2023cites this paper
• Contingent administration of typical and biased kappa opioid agonists reduces cocaine and oxycodone choice in a drug vs. food choice procedure in male rhesus monkeys

  2023cites this paper
• Discovery and Validation of Context-Dependent Synthetic Mammalian Promoters

  2023cites this paper
• HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain-induced lung inflammation

  2023cites this paper
• Dynamic Insights into the Self-Activation Pathway and Allosteric Regulation of the Orphan G-Protein-Coupled Receptor GPR52

  2023cites this paper
• A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics

  2023cites this paper
• A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells

  2023cites this paper
• Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.

  2022cites this paper
• Psychedelics as potent anti-inflammatory therapeutics.

  2022cites this paper
• G protein–coupled receptor interactions with arrestins and GPCR kinases: The unresolved issue of signal bias

  2022cites this paper
• 5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics.

  2022cites this paper
• Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies

  2022cites this paper
• Structural pharmacology of PTH and PTHrP.

  2022cites this paper
• Dose-Dependent Regulation on Prefrontal Neuronal Working Memory by Dopamine D1 Agonists: Evidence of Receptor Functional Selectivity-Related Mechanisms

  2022cites this paper
• A Dopamine D1 Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory

  2022cites this paper
• Dopamine D1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, behavior, and neurophysiology.

  2022cites this paper
• Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor

  2022cites this paper